Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News EOM Pharmaceutical Holdings Inc IMUC

Healthcare Biotechnology
EOM Pharmaceutical Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing novel drugs for patients suffering from debilitating and deadly diseases, including infectious diseases; autoimmune diseases including rheumatoid arthritis; and cachexia associated with acquired immune deficiency syndrome (AIDS) and cancer. It has two pipeline assets in their... see more

Recent & Breaking News (PINL:IMUC)

ImmunoCellular Therapeutics Announces 2015 Financial Results

PR Newswire March 30, 2016

ImmunoCellular Therapeutics to Report 2015 Financial Results on March 30, 2016

PR Newswire March 29, 2016

ImmunoCellular Therapeutics to Present at ROTH Conference on March 16, 2016

PR Newswire March 7, 2016

Cryoport Supports ImmunoCellular Therapeutics' 120-Site Phase III Clinical Trial With Cold Chain Logistics

PR Newswire March 3, 2016

ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University to Advance Stem-to-T-Cell Program

Press Releases February 16, 2016

CYREN WebSecurity 3.0 Stops New Generation of Zero-Day Cyber Threats Using Industry's First Cloud Sandbox Array

Press Releases February 16, 2016

ImmunoCellular Therapeutics to Present at the BIO CEO & Investor Conference on February 8, 2016

PR Newswire February 1, 2016

ImmunoCellular Therapeutics Enters into a Sponsored Research Agreement with The University of Maryland, Baltimore to Pursue Multiple Enhancements of its Cancer Immunotherapy Platforms

PR Newswire January 27, 2016

A Look at Four Brain Cancer Companies for 2016

Accesswire January 4, 2016

ImmunoCellular Therapeutics' Andrew Gengos Interviewed by The Life Sciences Report

Marketwired December 17, 2015

ImmunoCellular Therapeutics Establishes Agreement with The Canadian Brain Tumour Consortium for ICT-107 Phase 3 Registrational Trial in Glioblastoma

PR Newswire December 14, 2015

ImmunoCellular Therapeutics Presentation Now Available for On-Demand Viewing

Canada NewsWire December 7, 2015

ImmunoCellular Therapeutics Establishes Agreement with Alliance Foundation Trials, LLC for ICT-107 Phase 3 Registrational Trial in Glioblastoma

PR Newswire December 7, 2015

NYSE, Nasdaq and OTC Companies to Present Online to Investors on December 3

Canada NewsWire December 1, 2015

ImmunoCellular Therapeutics to Webcast, Live, at VirtualInvestorConferences.com December 3

Canada NewsWire December 1, 2015

ImmunoCellular Therapeutics Establishes Agreement with EORTC for ICT-107 Phase 3 Registrational Trial in Glioblastoma

PR Newswire December 1, 2015

ImmunoCellular Therapeutics to Host Conference Call and Webcast to Discuss ICT-107 Program in Newly Diagnosed Glioblastoma on November 24, 2015

PR Newswire November 23, 2015

ImmunoCellular Therapeutics Presents Updated ICT-107 Phase 2 Survival and Immune Response Data at the Society for Neuro-Oncology Annual Meeting 2015

PR Newswire November 20, 2015

ImmunoCellular Therapeutics Enters into Sponsored Research Agreement with University of Texas MD Anderson Cancer Center to Advance Stem-to-T-Cell Program

PR Newswire November 12, 2015

ImmunoCellular Therapeutics Announces Third Quarter 2015 Financial Results

PR Newswire November 10, 2015